Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Liabilities and Shareholders Equity (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $764.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 23.36% year-over-year to $764.0 million, compared with a TTM value of $3.4 billion through Sep 2025, up 7.52%, and an annual FY2024 reading of $956.9 million, up 60.73% over the prior year.
  • Liabilities and Shareholders Equity was $764.0 million for Q3 2025 at Bicycle Therapeutics, down from $832.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q2 2024 and bottomed at $223.8 million in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $584.2 million, with a median of $479.8 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity surged 197.73% in 2021, then decreased 23.36% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $479.8 million in 2021, then decreased by 14.42% to $410.6 million in 2022, then surged by 44.99% to $595.3 million in 2023, then soared by 60.73% to $956.9 million in 2024, then dropped by 20.16% to $764.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BCYC at $764.0 million in Q3 2025, $832.2 million in Q2 2025, and $883.9 million in Q1 2025.